Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | Managing patients with transplant-ineligible BDPCN with tagraxofusp

Marco Herling • 25 Apr 2023
EBMT 2023
Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Tagraxofusp

Marco Herling, MD, University of Leipzig, Leipzig, Germany, comments on the management of transplant-ineligible patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), explaining that patients should be treated with tagraxofusp due to its tolerable toxicity profile. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marco Herling

Unmet needs in BPDCN: CNS involvement & the importance of intrathecal chemotherapy prophylaxis
1:00
Unmet needs in BPDCN: CNS involvement & the importance of intrathecal chemotherapy prophylaxis
Marco Herling • 25 Apr 2023
Improvements in the awareness and diagnosis of BPDCN
1:41
Improvements in the awareness and diagnosis of BPDCN
Marco Herling • 25 Apr 2023
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
1:23
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
Marco Herling • 25 Apr 2023
Frontline treatment in BPDCN & the best route to allogeneic transplantation
3:07
Frontline treatment in BPDCN & the best route to allogeneic transplantation
Marco Herling • 25 Apr 2023

Related Videos

Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
2:14
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
Ashutosh Wechalekar • 9 Sep 2026
Phase III CARES subgroup analysis: signal of benefit with anselamimab in kappa AL amyloidosis
3:04
Phase III CARES subgroup analysis: signal of benefit with anselamimab in kappa AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals